Targets › FST
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Sep 2027.
Multifunctional regulatory protein whose primary function is to antagonize members of the transforming growth factor beta (TGF-beta) superfamily including activin, myostatin, GDF11 or bone morphogenetic proteins (BMPs). Mechanistically, binds to these ligands in the extracellular space, blocking their type II receptor-binding site to inhibit downstream signaling. (UniProt, P19883)
Open in Phaseline: the race on FST, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Unlimited Biotechnology | AAV9-Follistatin gene therapy Adeno-associated virus serotype 9 vector encoding human follistatin to increase muscle mas | FST | Phase 1 | Age-related Muscle Decline | Sep 2027 |
Age-related Muscle Decline (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.